ADPORT

Brand name authorized in: Austria Finland Netherlands

Active ingredients

The drug ADPORT contains one active pharmaceutical ingredient (API):

1 Tacrolimus
UNII WM0HAQ4WNM - TACROLIMUS

Tacrolimus is a highly potent immunosuppressive agent. In particular, tacrolimus inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection. Tacrolimus suppresses T-cell activation and T-helper-cell dependent B-cell proliferation, as well as the formation of lymphokines (such as interleukins-2, -3, and γ-interferon) and the expression of the interleukin-2 receptor.

Read about Tacrolimus

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
Tacrolimus
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AD Calcineurin inhibitors
Discover more medicines within L04AD02

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
FI
Lääkealan turvallisuus- ja kehittämiskeskus
Identifier(s): 049301, 059757, 114502, 402253, 577142
NL
Z-Index G-Standaard, PRK
Identifier(s): 197165, 92363, 92371, 92398